Efficacy and Safety of Transarterial Chemoembolization and Repeated Partial Splenic Embolization for Hepatocellular Carcinoma with Hypersplenism and Thrombocytopenia
DOI: https://doi.org/10.2147/jhc.s455461
2024-06-12
Journal of Hepatocellular Carcinoma
Abstract:Wei Hong, 1, 2 Zizhuo Wang, 1, 2 Wei Yao, 1, 2 Xin Zhang, 1, 2 Lijie Zhang, 1, 2 Bin Liang 1, 2 1 Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China; 2 Hubei Key Laboratory of Molecular Imaging, Wuhan, Hubei, People's Republic of China Correspondence: Bin Liang, Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Road, Wuhan, 430022, People's Republic of China, Tel +86 27 85726432, Fax +86 27 85727002, Email Aim: Partial splenic embolization (PSE) combined with transarterial chemoembolization (TACE) has been reported in treatment of hepatocellular carcinoma (HCC) with cirrhotic hypersplenism and thrombocytopenia. However, efficacy and safety of repeated PSE when required are unclear. This study aims to investigate post-procedural changes in peripheral blood cell and hepatic function, progression-free survival (PFS), and safety of HCC patients with hypersplenism received TACE and repeated PSE compared to those received TACE alone. Methods: This retrospective study included 102 HCC patients with hypersplenism who received TACE (n = 73) or TACE+PSE (n = 29) from January 2014 to December 2021. Changes in peripheral blood cell and hepatic function were investigated at 1 week, 2, 6, 12, 18, and 24 months. TACE procedure sessions and adverse events were recorded. PFS and prognostic factors were analyzed. Results: Despite response to initial PSE being limited, repeated PSE increased platelet (PLT) again, which peaked at 18 months. It also continued to improve red blood cell (RBC) and hemoglobin, which showed significant differences in changes from baseline between two groups until 24 months, as well as Child-Pugh scores at 12 and 18 months. Mean TACE procedure sessions were significantly higher in TACE+PSE group than that in TACE alone group (4.55 vs 3.26, P = 0.019). TACE+PSE group had longer median PFS (19.4 vs 9.5 months, P = 0.023) than TACE alone group, where PSE was an independent protective factor (HR, 0.508; P = 0.014). Initial and repeated PSE showed no significant differences in safety. Conclusion: Repeated PSE is effective in increasing PLT again and improving RBC, hemoglobin and liver function. It contributed to performing serial TACE procedures thereafter. TACE combined with repeated PSE has significantly longer PFS than TACE alone, where PSE was an independent protective factor. Moreover, the safety of repeated PSE was comparable to initial PSE. Keywords: hepatocellular carcinoma, hypersplenism, transarterial chemoembolization, partial splenic embolization Hepatocellular carcinoma (HCC) accounts for most cases of primary liver cancer, which is the third-leading cause of cancer death worldwide. 1 As a critical risk factor for HCC, liver cirrhosis presents in up to 90% of HCC patients. 2 Hypersplenism is a well-known complication of cirrhosis and is characterized by hemocytopenia, particularly thrombocytopenia. 3 Thrombocytopenia may hinder the treatments for HCC due to the increased risk of bleeding. 4 Meanwhile, it has been shown that hypersplenism and thrombocytopenia are potentially associated with poor patient prognosis. 3 Partial splenic embolization (PSE) has become increasingly popular in the management of hypersplenism and thrombocytopenia induced by cirrhosis over recent years. 5–7 It has demonstrated effectiveness in improving platelet (PLT) count as a minimally invasive alternative to splenectomy. Previous studies have shown that the increment of PLT after PSE greatly depends on the splenic infarction ratio. 8 However, the incidence of complications after PSE also increases as the infarction ratio increases. Infarction ratio higher than 70% is associated with major complications such as splenic abscess, according to a systematic review. 9 PSE with lower infarction ratio is safer but less effective and more likely to relapse. In this situation, repeated PSE is expected. 10,11 Transarterial chemoembolization (TACE) is currently widely used for unresectable HCC. 2 To date, several researchers have reported the beneficial effects of TACE combined with concurrent PSE in HCC patients with hypersplenism and thrombocytopenia. 12–18 Nevertheless, some patients were lack of response to initial PSE, resulting in unsatisfactory PLT count during the follow-up period. 13 For these patients, repeated PSE was conceivably required. To the best of our knowledge, no stud -Abstract Truncated-
oncology